2-[(4-Methylpiperazin-1-yl)methyl]pyrazine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-[(4-Methylpiperazin-1-yl)methyl]pyrazine
• 英文别名: 2-[(4-methylpiperazin-1-yl)methyl]pyrazine
• 化学式: C₁₀H₁₆N₄
• 分子量: 192.26
• InChiKey: SFEFMMUQDPWUQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINES COMME INHIBITEURS DE LA KINASE RET
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2017011776A1

  公开（公告）日：2017-01-19

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供了一般式I的化合物及其立体异构体和药用可接受的盐或溶剂，其中A、B、D、E、X1、X2、X3和X4的含义如规范中所述，这些化合物是RET激酶的抑制剂，可用于治疗和预防可以用RET激酶抑制剂治疗的疾病，包括由RET激酶介导的疾病或紊乱。
• [EN] SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRAZINE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ANDREWS STEVEN W

  公开号：WO2018136661A1

  公开（公告）日：2018-07-26

  Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供了Formula I的化合物及其立体异构体和药学上可接受的盐或溶剂，其中A、B、D、E、X1、X2、X3和X4在规范中给出的含义，这些化合物是RET激酶的抑制剂，可用于治疗和预防可以用RET激酶抑制剂治疗的疾病，包括由RET激酶介导的疾病或紊乱。
• NEW CHEMICAL COMPOUNDS (DERIVATIVES) AND THEIR APPLICATION FOR THE TREATMENT OF ONCOLOGICAL DISEASES
  申请人：Limited Liability Company "National Pharmaceutical Technologies"

  公开号：EP3050884B1

  公开（公告）日：2019-04-03
• SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
  申请人：Array BioPharma, Inc.

  公开号：US20170096425A1

  公开（公告）日：2017-04-06

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X 1 , X 2 , X 3 and X 4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
• [EN] NOVEL CHEMICAL COMPOUNDS (VARIANTS) AND THE USE THEREOF TO TREAT ONCOLOGICAL DISEASES<br/>[FR] NOUVEAUX COMPOSÉS CHIMIQUES, VARIANTES, ET LEUR UTILISATION POUR TRAITER DES MALADIES ONCOLOGIQUES<br/>[RU] НОВЫЕ ХИМИЧЕСКИЕ СОЕДИНЕНИЯ (ВАРИАНТЫ) И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ
  申请人：LTD LIABILITY COMPANY NAT PHARMACEUTICAL TECHNOLOGIES

  公开号：WO2015047133A1

  公开（公告）日：2015-04-02

  Изобретение относится к новым химическим соединениям общей формулы I, в которых LA, LB, LC, цикл A, цикл B, RA, RB, RC, RD, RE и RF имеют значения, указанные в описании, и которые являются ингибиторами протеинкиназ. Изобретение также относится к фрмацевтическим композициям, содержащим указанные соединения, а также к применению вышеуказанных соединений для лечения и/или предотвращения заболеваний, связанных с аберрантной активностью протеинкиназ.